Logo image of SIGA

SIGA TECHNOLOGIES INC (SIGA) Stock Price, Quote, News and Overview

NASDAQ:SIGA - Nasdaq - US8269171067 - Common Stock - Currency: USD

6.07  +0.22 (+3.76%)

After market: 6.4 +0.33 (+5.44%)

SIGA Quote, Performance and Key Statistics

SIGA TECHNOLOGIES INC

NASDAQ:SIGA (2/10/2025, 8:23:02 PM)

After market: 6.4 +0.33 (+5.44%)

6.07

+0.22 (+3.76%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High12.83
52 Week Low4.75
Market Cap433.22M
Shares71.37M
Float40.51M
Yearly Dividend0.45
Dividend Yield10.26%
PE5.06
Fwd PE4.72
Earnings (Next)02-27 2025-02-27/amc
IPO09-09 1997-09-09


SIGA short term performance overview.The bars show the price performance of SIGA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

SIGA long term performance overview.The bars show the price performance of SIGA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 10 -10 15

The current stock price of SIGA is 6.07 USD. In the past month the price decreased by -2.25%. In the past year, price increased by 17.86%.

SIGA TECHNOLOGIES INC / SIGA Daily stock chart

SIGA Latest News and Analysis

News Image
15 hours ago - Chartmill

Stay updated with the stocks that are on the move in today's after-hours session.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

News Image
a month ago - Benzinga

Japan Approves SIGA Technologies Antiviral As First For Smallpox, Mpox

Japan approves SIGA's TEPOXX for smallpox, mpox, and cowpox, expanding antiviral availability for orthopoxviruses with proven safety and efficacy.

News Image
a month ago - SIGA Technologies Inc.

TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses

Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno...

News Image
2 months ago - SIGA Technologies Inc.

Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced

Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy...

News Image
3 months ago - SIGA Technologies Inc.

SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced...

SIGA Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 66.84 824.85B
NVO NOVO-NORDISK A/S-SPONS ADR 26.55 372.57B
JNJ JOHNSON & JOHNSON 15.44 371.35B
AZN ASTRAZENECA PLC-SPONS ADR 20.13 225.33B
MRK MERCK & CO. INC. 11.31 218.56B
NVS NOVARTIS AG-SPONSORED ADR 13.63 213.62B
PFE PFIZER INC 8.32 146.61B
SNY SANOFI-ADR 13.45 133.58B
BMY BRISTOL-MYERS SQUIBB CO 48.71 112.62B
ZTS ZOETIS INC 29.85 77.56B
GSK GSK PLC-SPON ADR 7.91 74.41B
TAK TAKEDA PHARMACEUTIC-SP ADR 30.52 42.58B

About SIGA

Company Profile

SIGA logo image SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 45 full-time employees. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The firm's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The company uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.

Company Info

SIGA TECHNOLOGIES INC

31 East 62Nd Street

New York City NEW YORK 10065 US

CEO: Phillip L. Gomez

Employees: 45

Company Website: https://www.siga.com/

Investor Relations: https://investor.siga.com/

Phone: 12126729100

SIGA FAQ

What is the stock price of SIGA?

The current stock price of SIGA is 6.07 USD.


What is the symbol for SIGA TECHNOLOGIES INC stock?

The exchange symbol of SIGA TECHNOLOGIES INC is SIGA and it is listed on the Nasdaq exchange.


On which exchange is SIGA stock listed?

SIGA stock is listed on the Nasdaq exchange.


Is SIGA a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SIGA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SIGA.


Does SIGA stock pay dividends?

SIGA has a dividend yield of 10.26%. The yearly dividend amount is currently 0.45.


When does SIGA stock report earnings?

SIGA will report earnings on 2025-02-27, after the market close.


What is the Price/Earnings (PE) ratio of SIGA?

The PE ratio for SIGA is 5.06. This is based on the reported non-GAAP earnings per share of 1.2 and the current share price of 6.07 USD.


What is the Short Interest ratio of SIGA stock?

The outstanding short interest for SIGA is 8.39% of its float.


SIGA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to SIGA. When comparing the yearly performance of all stocks, SIGA is one of the better performing stocks in the market, outperforming 70.7% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SIGA Fundamental Analysis

ChartMill assigns a fundamental rating of 8 / 10 to SIGA. SIGA scores excellent points on both the profitability and health parts. This is a solid base for a good stock.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SIGA Financial Highlights

Over the last trailing twelve months SIGA reported a non-GAAP Earnings per Share(EPS) of 1.2. The EPS decreased by 1814.29% compared to the year before.


Industry RankSector Rank
PM (TTM) 49.33%
ROA 43.87%
ROE 50.58%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%300%
Sales Q2Q%8.33%
EPS 1Y (TTM)1814.29%
Revenue 1Y (TTM)399.23%

SIGA Ownership and Analysts

For the next year, analysts expect an EPS growth of 12.74% and a revenue growth 44.62% for SIGA


Ownership
Inst Owners49.42%
Ins Owners8.57%
Short Float %8.39%
Short Ratio7.61
Analysts
Analysts0
Price TargetN/A
EPS Next Y12.74%
Revenue Next Year44.62%